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LETTERS TO THE EDITOR
Reverse epidemiology and
hemodialysis blood pressure
To the Editor: Analyzing reverse causality in dialysis,
Kalantar-Zadeh et al [1] address the blood pressure (BP)
control issue and refer to Tassin unit experience in this
issue of Kidney International.
In the studies cited by the authors, BP figures used
as risk predictor are baseline values, most patients are
hypertensive, antihypertensives are used in 65%, follow-
up time is <5 years, and extracellular volume (ECV) is
not mentioned. Conversely, in our own studies [2, 3],
integrated BP values are used, BP is strictly normal,
antihypertensives are seldom used, follow-up time is
>10 years, and ECV control is a key point. Among 1235
Tassin patients, the lowest initial predialysis BP decile
(1st dialysis month mean arterial pressure <90 mm Hg)
mortality is significantly high (2 years odds ratio = 1.96,
P < 0.02). Therefore, in Tassin as elsewhere, initially low
BP does predict early mortality.
BP predictive value at dialysis initiation is poor: 90%
of patients then are hypertensive, whatever their former
hypertension exposure duration, and whether or not they
become normotensive in dialysis. The effect of hyperten-
sion on target organs takes many years and very often
we don’t know how long a patient starting dialysis has
been hypertensive. A recent report [4] clearly confirms
the crucial predictive importance of hypertension dura-
tion before dialysis.
Reverse epidemiology has misleading relevance on
dialysis management. The high early mortality univer-
sally associated with low baseline BP figures does not
contradict the need to achieve normal BP in dialysis
patients to reduce long-term cardiovascular mortality.
Besides, the eventual noxious/beneficial role of antihy-
pertensive medications in dialysis patients needs to be
investigated.
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Reply from the Authors
Charra et al [1] indicate that in Tassin, a low, rather
than elevated, blood pressure (BP) is associated with an
almost 2-fold increase in mortality among maintenance
hemodialysis (MHD) patients, despite long hours of dial-
ysis treatment. This is consistent with our stated theory of
reverse epidemiology. The study quoted by the authors in-
dicating a positive association between hypertension and
mortality in 184 Spanish MHD patients had a relatively
small sample size [2]. Moreover, patients in this study
were, on average, 10 years younger than MHD patients
in the United States [3]. On the contrary, the epidemio-
logic studies indicating a strong association between low
BP and mortality in MHD patients, which we [1] referred
to, or which have been published elsewhere [4], examined
many thousands of MHD patients with a low likelihood
of selection bias.
It is not well established that treatment of hyperten-
sion by altering hemodialysis techniques or lengthening
dialysis hours improves survival by reducing BP. Such
treatments almost certainly change many other physio-
logic and metabolic conditions concurrently. Nonethe-
less, it is quite possible that if MHD patients lived longer,
traditional risk factors such as hypertension might have
the time necessary to exert their long-term deleterious
effects. However, in MHD patients, malnutrition-
inflammation complex syndrome (MICS) may indepen-
dently cause high early mortality and reverse traditional
risk factors [1]. Thus, it is possible, although not proven,
that alleviation of MICS saves lives. Given the high mor-
tality in MHD patients and failure of traditional risk
factors to explain this, randomized clinical trials that
test whether treatment of MICS reduces mortality are
strongly indicated.
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Inadequacy of antiretroviral
drugs dosage adjustment in
HIV patients receiving dialysis
Letter to the Editor: Szczech et al [1] reported an
interesting study in a recent issue of Kidney International.
The authors reported the antiretroviral drugs dosing reg-
imens they observed in their hemodialyzed patients. We
further analyzed these dosing regimens and it appeared
that dosage adjustement were most often inadequate for
those patients with end-stage renal disease.
Table 1. Comparison of antiretroviral dosage reported in Szczech’s
study and available dosing recommendations for hemodialysis
patients [2]
Recommended
Drug N Dosage dosage
Nucleoside reverse transcriptase inhibitors
Abacavira 3 300 to 600 mg/day 1200 mg/day
Didanosine 7 100 to 400 mg/day 50 to 100 mg/day
Lamivudine 36 25 to 300 mg/day 150 mg first dose then
25 to 50 mg/day
Stavudine 33 10 to 40 mg/day 15 to 20 mg/day
Zidovudine 11 100 mg 3 × a week 300 mg/day
to 600 mg/day
Combivir 8
Lamivudine 150 to 450 mg/day 150 mg first dose then
25 to 50 mg/day
Zidovudine 300 to 900 mg/day 300 mg/day
Non-nucleoside reverse transcriptase inhibitors
Efavirenza 13 200 to 600 mg/day 600 mg/day
Nevirapinea 11 200 to 400 mg/day 200 to 400 mg/day
Protease inhibitors
Indinavira 6 1600 to 2400 mg/day 2400 mg/day
Nelfinavira 21 500 to 2500 mg/day 2250 mg/day
Ritonavira 5 200 to 1000 mg/day 1200 mg/day
Saquinavira 2 800 to 3600 mg/day 1800 mg/day
N = Number of patients in Szczech’s study.
Combivir, 1 capsule contains 150 mg lamivudine and 300 mg zidovudine.
aDrug for which dosage adjustment is not necessary in hemodialyzed patients.
We read with great interest Szczech’s article [1], in
which they concluded that antiretroviral medications
were not used at their optimal dose in the human
immunodeficiency virus (HIV) hemodialysis patients
they studied because data on these drugs’ pharmacoki-
netics and dosage adjustment in patients with renal insuf-
ficiency are lacking. However, we would like to outline
that most antiretroviral drugs’ pharmacokinetics have
been studied in patients with renal insufficiency.
Based on those publications and our personal data, we
have recently published precise guidelines on antiretro-
viral drug dosage adjustment in hemodialysis patients [2].
Among the 11 antiretroviral drugs reported in Szczech’s
article, only 1 was administered at the correct dose (nevi-
rapine). The other drugs that should have been prescribed
at their usual dosage were either underdosed (abacavir,
efavirenz, indinavir, nelfinavir, ritonavir, saquinavir) or
overdosed (saquinavir). For the latter, the usual recom-
mended dose for hemodialysis patients is 1800 mg/day
[2]; the dosing range reported by Szczech is 800 to
3600 mg/day. Among the drugs that should have had their
dose adjusted according to the patients’ renal function,
didanosine was clearly overdosed. Stavudine, lamivudine,
and zidovudine administered alone were either under- or
overdosed. Finally, the use of the lamivudine-zidovudine
combination drug Combivir led to a large overdose in
all cases.
Consequently, although we agree that further pharma-
cokinetic, tolerance, and efficacy studies are mandatory
for these patients, dose adjustment recommendations
exist [2] and should already be routinely applied.
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Calcimetic AMG 073 at 50
and 100 mg per day
To the Editor: A comparison of the assessment against
placebo of the calcimimetic AMG 073 at 50 [1] and
